Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
中国成年人接种SARS-CoV-2 BNT162b1 mRNA疫苗后的免疫持久性和安全性:一项随机、安慰剂对照、双盲1期试验
期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02206-1
Li, Jingxin; Hui, Ai-Min; Zhang, Xiang; Ge, Lei; Qiu, Yuanzheng; Tang, Rong; Ye, Huayue; Wang, Xiyuan; Lin, Mei; Zhu, Zhongkui; Zheng, Jianfei; Qiu, Jingjun; Lagkadinou, Eleni; Shpyro, Svetlana; Ozhelvaci, Orkun; Türeci, Özlem; Khondker, Zakaria; Yin, Wanrong; Shishkova, Yoana; Jia, Siyue; Pan, Hongxing; Peng, Fuzhong; Ma, Zhilong; Wu, Zhenggang; Guo, Xiling; Shi, Yunfeng; Muik, Alexander; Şahin, Uğur; Zhu, Li; Zhu, Fengcai